Metastatic Colorectal Cancer (mCRC)Phase 1NCT02069704
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
A Phase 1 study testing Bevacizumab biosimilar (BEVZ92) and Avastin® (bevacizumab, reference product) in people with Metastatic Colorectal Cancer (mCRC), run by mAbxience Research S.L. at 18 sites in 5 countries.
Trial summary
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Colorectal Cancer (mCRC)
- What is being tested?
- Bevacizumab biosimilar (BEVZ92) and Avastin® (bevacizumab, reference product)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 142 participants
- Where
- 18 sitesin 5 countries
- Study dates
- 29 Oct 2014to Jun 2017
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must not have had prior chemotherapy for advanced or metastatic disease. Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.
- Patient with mCRC for whom bio-chemotherapy is indicated.
- Patients must have at least one measurable non-irradiated site of disease according to RECIST (version 1.1) criteria. If the patient has had previous irradiation of the marker lesion(s), there must be evidence of progression since the radiation.
- Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Adequate bone marrow function
Show all 12Show fewer
- Adequate liver function defined within specific parameters
- Adequate renal function defined within specific parameters
- Adequate coagulation parameters defined within specific parameters
- Negative pregnancy test for females of a childbearing potential.
- Use of an effective form of contraception during the study (for subjects of childbearing potential and their partners).
- Life expectation ≥ 3 months
Who cannot join
- Prior treatment for advanced or metastatic colorectal cancer.
- Prior treatment with an anti-angiogenesis agent, in either the neoadjuvant or adjuvant setting.
- Concurrent use of investigational anti-neoplastic agents (including up to 4 weeks prior to enrolment).
- History of any other malignancy unless the malignancy is in complete remission and the patient has been off all therapy for that malignancy for at least 5 years.
- Chronic treatment with systemic steroids or other immunosuppressive agents; topical or inhaled corticosteroids are allowed.
- Scheduled immunization with attenuated live vaccines during study period or within 1 week prior to study entry.
Show all 14Show fewer
- Uncontrolled brain or lepto-meningeal metastases, including patients who continue to require glucocorticoids for brain or lepto-meningeal metastases.
- Patients with active bleeding or history of bleeding diathesis on oral anti-vitamin K medication (except low dose coumadin) within the past 6 month prior to randomization or coagulopathy.
- Patients with history of cerebral vascular accident, transient ischemic attack, or subarachnoid haemorrhage within the past 6 month prior to randomization.
- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
- Patients with serious non-healing wound, ulcer, bone fracture, or with a major surgical procedure, or significant traumatic injury within 4 weeks prior to randomization
- Patients with clinical symptoms or signs of gastrointestinal obstruction that require parenteral hydration and/or nutrition.
- Patients with history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months prior to randomization.
- Patients with history of hypersensitivity to any of the study drugs or ingredients.
Trial locations and contacts
18 sites in 5 countries.
18 sites in 5 countries
Brazil6 sites
Fundaçáo Pio XII - Hospital do Cancer de Barretos
Barretos
Hospital Caridade
Ijuí
Hospital Sao Lucas da Pucrs
Porto Alegre
Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC
São Paulo
Hosp. A.C Camargo
São Paulo
Instituto do Cancer del estado de S. Paulo (ICEPS )
São Paulo
India6 sites
Sri Ramachandra Hospital
Chennai
M S Patel Cancer Centre- Shree Krishna Hospital
Karamsad, Gujarat, 388 325
Tata Hospital
Mumbai
Central India Canter Research Institute
Nagpur
Curie Manavta Cancer Center
Nashik
Regional Cancer Center & Medical College
Thiruvananthapuram
Ukraine3 sites
Dnipropetrovsk City Multiple-discipline Clinical Hospital №4
Dnipropetrovsk
Kharkiv Regional Clinical Oncology Center
Kharkiv
Danylo Halytskiy Lviv National Medical University
Lviv
Argentina2 sites
Hospital de Gastroenterologia "Dr. Carlos Bonorino Udaondo"
Buenos Aires
Instituto Oncológico de Rosario
Rosario
About this study
Official title: Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX (any) or FOLFIRI chemotherapy.
FOLFOX (any) or FOLFIRI will be chosen as per investigator criteria based on the hospital standard of care.
Read the detailed description
Planned enrolment duration: 12 months. Pre-treatment period (included in enrolment period): 1 month. Treatment period: Patients will continue treatment until disease progression or unacceptable toxicity, or withdrawal of consent.
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Being tested
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Keywords
- colorectal cancer, metastatic, first-line treatment, comparability
- Medical subject headings
- Colorectal Neoplasms, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bevacizumab biosimilar (BEVZ92)Drug
Also called FOLFOX = Folinic acid + Fluorouracil + Oxaliplatin, FOLFIRI = Folinic acid + Fluorouracil + Irinotecan
Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).
FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).
*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.
The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
Avastin® (bevacizumab, reference product)Drug
Also called FOLFOX = Folinic acid + Fluorouracil + Oxaliplatin, FOLFIRI = Folinic acid + Fluorouracil + Irinotecan
Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).
*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.
The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
| Study group | Role | What they receive |
|---|---|---|
| Bevacizumab biosimilar (BEVZ92) | Experimental | Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). Receives: Drug: Bevacizumab biosimilar (BEVZ92) |
| Avastin® (bevacizumab, ref. product) | Active comparator | Bevacizumab 25mg/ml (strength: 100mg/4ml) Receives: Drug: Avastin® (bevacizumab, reference product) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin®
To compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated AUC calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1; AUC0-336h)
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%.
Measured: AUC0-336 hrs: 0 to 336 hours after start of the first infusion
AUC at Steady State (AUCss) of BEVZ92 and Avastin®
To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated area under the concentration-versus-time curve calculated over a dosage interval at steady state (i.e. at Cycle 7; AUCss).
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%.
Measured: AUCss: 0 to 336 hours after the administration of Cycle 7 infusion (Week 13).
Secondary outcomes (11)
Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Reported With BEVZ92 and Avastin®
Compare the safety profile by means of the frequency and severity of TEAEs and SAEs reported in each treatment arm.
Measured: From first study dose and up to 30 days after the end of study treatment for each patient, for an average of 11 months
Anti-Drug Antibody (ADA) of BEVZ92 and Avastin®
Immunogenicity profile by means of measurement of ADA developed de novo (seroconversion) after cycle 5, cycle 8, and 12 months after first drug administration (pre-dose).
Measured: At baseline, and on Day 1 (pre-dose) of Cycles: 1, 5 and 8, and 12 months after first drug administration
Objective Response Rate (ORR) of BEVZ92 and Avastin®
To compare efficacy in terms of ORR between arms. Clinical and radiological tumor assessments were performed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Objective response (OR) is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders.
Measured: Every four weeks. Up to 48 weeks
Cmax,sd of BEVZ92 and Avastin®
Secondary PK endpoints included the Cmax calculated at Cycle 1 (Cmax,sd )
Measured: Cmax, sd: 0 to 336 hours after start of the first infusion.
Progression-free Survival (PFS) of BEVZ92 and Avastin®
Compare PFS between the randomized treatment arms. Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions plus 5 mm absolute increase, and/or unequivocal progression of known non-target lesion, and/or the appearance of new lesions".
Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 weeks.
Cmax,ss of BEVZ92 and Avastin®
Secondary PK endpoints included the Cmax calculated at Cycle 7 (Cmax, ss )
Measured: Cmax, ss: 0 to 336 hours post-dose after the administration of Cycle 7 infusion (Week 13)
Ctrough,sd of BEVZ92 and Avastin®
Secondary PK endpoints included the Ctrough calculated at Cycle 1 (Ctrough,sd )
Measured: Ctrough, sd: 0 to 336 hours after start of the first infusion.
Ctrough,ss of BEVZ92 and Avastin®
Secondary PK endpoints included the Ctrough calculated at Cycle 7 (Ctrough,ss)
Measured: Ctrough, ss: 0 to 336 hours after the administration of the Cycle 7 infusion.
Elimination Half-life (t1/2) of BEVZ92 and Avastin®
Secondary PK endpoints included the t1/2 calculated at Cycle 7
Measured: t1/2: 0 to 336 hours after the administration of the Cycle 7 infusion.
Elimination Rate Constant (Kel) of BEVZ92 and Avastin®
Secondary PK endpoints included the Kel calculated at Cycle 7 (Ctrough,ss)
Measured: Kel: 0 to 336 hours after the administration of the Cycle 7 infusion.
Volume of Distribution (Vd) of BEVZ92 and Avastin®
Secondary PK endpoints included the Vd calculated at Cycle 7
Measured: Vd: 0 to 336 hours after the administration of the Cycle 7 infusion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2014 (estimated)
- Study start29 Oct 2014
- Primary completionOct 2015
- Study completionJun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Metastatic Colorectal Cancer (mCRC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 142 participants (actual)
Sponsor and investigators
- Lead sponsor
- mAbxience Research S.L.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Laboratorio Elea Phoenix S.A., Libbs Farmacêutica LTDA
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02069704
- Sponsor's protocol ID
- BEVZ92-A-01-13
- Other IDs
- BEVZ92-A-01-13
- Status last verified
- Jul 2019
- First submitted
- 14 Feb 2014
- Last updated
- 23 Jul 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Romera A, Peredpaya S, Shparyk Y, Bondarenko I, Mendonca Bariani G, Abdalla KC, Roca E, Franke F, Melo Cruz F, Ramesh A, Ostwal V, Shah P, Rahuman SA, Paravisini A, Huerga C, Del Campo Garcia A, Millan S. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018 Dec;3(12):845-855. doi: 10.1016/S2468-1253(18)30269-3. Epub 2018 Sep 24.
PubMed 30262136